Surgical Oncology
-
STAS is Associated with Poor Prognosis in Early-Stage NSCLC Regardless of Surgical Approach
JCOG0802/WJOG4607L data validate segmentectomy as non-inferior to lobectomy, regardless of the presence of STAS, Dr. Yasushi Yatabe said.
-
Novel Meta-Analysis Shows VATS Improves Overall Survival in Early-Stage Lung Cancer
Dr. Jacie Jiaqi Law shared results from a first-ever meta-analysis demonstrating that VATS reduces mortality risk without compromising disease-free survival.
-
Perioperative Nivolumab Proves Safe, Effective for Patients with Resectable Early-Stage NSCLC
Dr. Jonathan Spicer shared patient-reported outcomes data from CheckMate 77T showing the regimen is both safe and tolerable for patients.
-
Beyond the Scalpel: Improving Lung Resection Outcomes with Enhanced Recovery After Surgery Protocols
Dr. Cezary T. Piwkowski says growing literature suggests that optimized preoperative preparation or “prehabilitation” is critical to improving early postoperative outcomes.
-
Study Finds Correlations Between Certain Factors, Rates of Nodal Upstaging
Dr. Stella Martinez recently shared the latest data and explored the challenges and opportunities in lung cancer surgery in Latin America.
-
Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data
Surgeon Erin Gillaspie, MD, said surgery still has a role in the treatment of mesothelioma while medical oncologist Hedy Kindler, MD, said newer systemic therapies make surgery obsolete in this space.
-
Recurrence Remains a Risk Even for Patients Diagnosed via Screening
Drs. Sara Ghandehari and Weijia Chua discuss how to best monitor patients when guidelines and protocols vary and more research is needed.
-
ELCC Session Offers Surgical Perspective in Context of Neoadjuvant Immunotherapy
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC.
-
Radiation Oncologist Makes Case for Radiotherapy for Local Treatment of Select Patients
Can radiotherapy replace surgery in stage III NSCLC in the era of immunotherapy? During ELCC 23, Dr. Sara Ramella turned to the data to answer that question.
-
Guideline-Concordant Surgery, Adjuvant Therapy, and the Promise of Curative-Intent Lung Cancer Surgery: What Are We Up Against?
In a “tale of two trials,” Drs. Ogbeide and Osarogiagbon use insights from the ALCHEMIST trial population to try to understand outcomes disparities between North America and Japan.
View ILCN Archives
Provider Resources